These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Regulation of FGF8 expression by the androgen receptor in human prostate cancer. Gnanapragasam VJ; Robson CN; Neal DE; Leung HY Oncogene; 2002 Aug; 21(33):5069-80. PubMed ID: 12140757 [TBL] [Abstract][Full Text] [Related]
6. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence. Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214 [TBL] [Abstract][Full Text] [Related]
7. Prosaposin upregulates AR and PSA expression and activity in prostate cancer cells (LNCaP). Koochekpour S; Lee TJ; Wang R; Culig Z; Delorme N; Caffey S; Marrero L; Aguirre J Prostate; 2007 Feb; 67(2):178-89. PubMed ID: 17044040 [TBL] [Abstract][Full Text] [Related]
8. Enhanced androgen receptor signaling correlates with the androgen-refractory growth in a newly established MDA PCa 2b-hr human prostate cancer cell subline. Hara T; Nakamura K; Araki H; Kusaka M; Yamaoka M Cancer Res; 2003 Sep; 63(17):5622-8. PubMed ID: 14500404 [TBL] [Abstract][Full Text] [Related]
9. Expression of the forkhead transcription factor FOXP1 is associated both with hypoxia inducible factors (HIFs) and the androgen receptor in prostate cancer but is not directly regulated by androgens or hypoxia. Banham AH; Boddy J; Launchbury R; Han C; Turley H; Malone PR; Harris AL; Fox SB Prostate; 2007 Jul; 67(10):1091-8. PubMed ID: 17477366 [TBL] [Abstract][Full Text] [Related]
10. Ligand-independent activation of the androgen receptor by the differentiation agent butyrate in human prostate cancer cells. Sadar MD; Gleave ME Cancer Res; 2000 Oct; 60(20):5825-31. PubMed ID: 11059779 [TBL] [Abstract][Full Text] [Related]
11. Hormonal regulation of beta2-adrenergic receptor level in prostate cancer. Ramberg H; Eide T; Krobert KA; Levy FO; Dizeyi N; Bjartell AS; Abrahamsson PA; Taskén KA Prostate; 2008 Jul; 68(10):1133-42. PubMed ID: 18454446 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of MAPK-signaling pathway promotes the interaction of the corepressor SMRT with the human androgen receptor and mediates repression of prostate cancer cell growth in the presence of antiandrogens. Eisold M; Asim M; Eskelinen H; Linke T; Baniahmad A J Mol Endocrinol; 2009 May; 42(5):429-35. PubMed ID: 19223455 [TBL] [Abstract][Full Text] [Related]
13. Androgen-induced Wnt signaling in preosteoblasts promotes the growth of MDA-PCa-2b human prostate cancer cells. Liu XH; Kirschenbaum A; Yao S; Liu G; Aaronson SA; Levine AC Cancer Res; 2007 Jun; 67(12):5747-53. PubMed ID: 17575141 [TBL] [Abstract][Full Text] [Related]
14. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells. Murthy S; Agoulnik IU; Weigel NL Prostate; 2005 Sep; 64(4):362-72. PubMed ID: 15754350 [TBL] [Abstract][Full Text] [Related]
15. Interleukin-8 signaling promotes androgen-independent proliferation of prostate cancer cells via induction of androgen receptor expression and activation. Seaton A; Scullin P; Maxwell PJ; Wilson C; Pettigrew J; Gallagher R; O'Sullivan JM; Johnston PG; Waugh DJ Carcinogenesis; 2008 Jun; 29(6):1148-56. PubMed ID: 18487223 [TBL] [Abstract][Full Text] [Related]
16. 5-Azacitidine restores and amplifies the bicalutamide response on preclinical models of androgen receptor expressing or deficient prostate tumors. Gravina GL; Marampon F; Di Staso M; Bonfili P; Vitturini A; Jannini EA; Pestell RG; Tombolini V; Festuccia C Prostate; 2010 Aug; 70(11):1166-78. PubMed ID: 20333699 [TBL] [Abstract][Full Text] [Related]
17. Antagonistic interaction between bicalutamide (Casodex) and radiation in androgen-positive prostate cancer LNCaP cells. Quéro L; Giocanti N; Hennequin C; Favaudon V Prostate; 2010 Mar; 70(4):401-11. PubMed ID: 19902473 [TBL] [Abstract][Full Text] [Related]
18. The androgen receptor pathway is by-passed in prostate cancer cells generated after prolonged treatment with bicalutamide. Hobisch A; Fritzer A; Comuzzi B; Fiechtl M; Malinowska K; Steiner H; Bartsch G; Culig Z Prostate; 2006 Mar; 66(4):413-20. PubMed ID: 16302272 [TBL] [Abstract][Full Text] [Related]
19. Phosphorylation/dephosphorylation of androgen receptor as a determinant of androgen agonistic or antagonistic activity. Wang LG; Liu XM; Kreis W; Budman DR Biochem Biophys Res Commun; 1999 May; 259(1):21-8. PubMed ID: 10334909 [TBL] [Abstract][Full Text] [Related]
20. Establishment and characterization of an androgen receptor-dependent, androgen-independent human prostate cancer cell line, LNCaP-CS10. Ishikura N; Kawata H; Nishimoto A; Nakamura R; Ishii N; Aoki Y Prostate; 2010 Apr; 70(5):457-66. PubMed ID: 19902465 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]